Loading
A phase 1/2 trial of toripalimab, carboplatin and cisplatin in lung cancer, run by Hangzhou DAC Biotechnology Co., Ltd., now recruiting.
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. is a phase 1/2, interventional study registered as NCT07559929 by Hangzhou DAC Biotechnology Co., Ltd., with a registry enrolment figure of 200 participants, started 2026-08-19 and due to reach its primary completion in 2028-06-01. Interventions recorded: DXC006; Toripalimab; Carboplatin; Cisplatin. Conditions listed: Small Cell Lung Cancer. Primary outcome: Progression Free Survival (PFS); 6-month progression-free survival rate; Recommended Phase 2 Dose (RP2D). Lung eligibility wording from the registry: "Histologically or cytologically confirmed small cell lung cancer (SCLC)". Sites: China. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents, Carboplatin and the tag lung-deep-dive.